Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
50.85 x 1 53.50 x 2
Post-market by (Cboe BZX)
50.90 +0.34 (+0.67%) 04/17/25 [NASDAQ]
50.85 x 1 53.50 x 2
Post-market 50.96 +0.06 (+0.12%) 16:51 ET
Profile for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Sanofi-Aventis S.A. ADR 46 AVENUE DE LA GRANDE ARMEE PARIS I0 75017 FRA

www.sanofi.com Employees: 82,878 P: 33-1-53-77-44-00

Sector:

Medical

Description:

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

Key Statistics

Overview:

Market Capitalization, $K 127,727,960
Enterprise Value, $K 136,989,648
Shares Outstanding, K 2,526,265
Annual Sales, $ 47,922 M
Annual Net Income, $ 6,016 M
Last Quarter Sales, $ 8,029 M
Last Quarter Net Income, $ 492,410 K
EBIT, $ 10,112 M
EBITDA, $ 13,993 M
60-Month Beta 0.57
% of Insider Shareholders 1.00%
% of Institutional Shareholders 14.04%
Float, K 2,501,002
% Float 99.00%
Short Volume Ratio 0.49

Growth:

1-Year Return 10.39%
3-Year Return -6.78%
5-Year Return 1.42%
5-Year Revenue Growth 13.70%
5-Year Earnings Growth 15.96%
5-Year Dividend Growth 27.59%

Per-Share Information:

Most Recent Earnings 0.70 on 01/30/25
Next Earnings Date 04/24/25 [BMO]
Earnings Per Share ttm 4.16
EPS Growth vs. Prev Qtr -55.41%
EPS Growth vs. Prev Year -21.35%
Annual Dividend Rate, $ 1.48
Annual Dividend Yield 2.92%
Most Recent Dividend 1.478 on 05/09/24
Next Ex-Dividends Date 05/09/24
Dividend Payable Date 06/06/24
Dividend Payout Ratio 35.91%

SNY Ratios

Ratio
Price/Earnings ttm 12.16
Price/Earnings forward 11.51
Price/Earnings to Growth 0.94
Return-on-Equity % 25.61%
Return-on-Assets % 14.72%
Profit Margin % 12.55%
Debt/Equity 0.21
Price/Sales 2.88
Price/Cash Flow 9.49
Price/Book 1.52
Book Value/Share 33.20
Interest Coverage 7.24

SNY Dividends

Date Value
05/09/24 $1.4780
05/30/23 $1.3750
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro